Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 20, 2026, 6:40 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 58 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Libido Clear all
Completed Phase 3 Interventional

Safety and Efficacy of LibiGel® for Treatment of Hypoactive Sexual Desire Disorder in Surgically Menopausal Women

NCT00657501
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
testosterone gel, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 65 Years · Female only
Enrollment
575 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
66
States / cities
Mobile, Alabama • Chandler, Arizona • Glendale, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Jul 20, 2026, 6:40 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

NCT07596212
View directory record Official record
Conditions
Early-stage Breast Cancer, Hypoactive Sexual Desire Disorder, Hormone Receptor Positive Breast Carcinoma, Breast Cancer
Interventions
Aromatase Inhibitors, Bupropion, GnRH agonist
Drug
Lead sponsor
University of Illinois at Chicago
Other
Eligibility
18 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional

Acupuncture for Sexual Dysfunction

NCT02070029
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (HSDD), Low Libido, Female Sexual Dysfunction (FSD)
Interventions
Acupuncture
Procedure
Lead sponsor
TriHealth Inc.
Other
Eligibility
18 Years to 55 Years · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 16, 2014 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 3 Interventional

Zestra in Women With Mixed Sexual Dysfunction

NCT00118495
View directory record Official record
Conditions
Sexual Dysfunction, Psychological
Interventions
Non-prescription Zestra(TM): patented formulation
Drug
Lead sponsor
QualiLife Pharmaceuticals
Industry
Eligibility
21 Years to 65 Years · Female only
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
13
States / cities
Tarzana, California • Aurora, Colorado • Aventura, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2007 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Results available

Endometrial Safety Study of Transdermal Testosterone (300 Mcg/Day) in Naturally Postmenopausal Women

NCT00467259
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, Placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
45 Years to 70 Years · Female only
Enrollment
1,271 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
115
States / cities
Birmingham, Alabama • Mobile, Alabama • Montgomery, Alabama + 97 more
Source: ClinicalTrials.gov public record
Updated Dec 14, 2011 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Phase 2 Interventional

Hypoactive Sexual Desire Disorder in Males

NCT04002661
View directory record Official record
Conditions
Low Libido
Interventions
Flibanserin, Placebo
Drug
Lead sponsor
Mohit Khera
Other
Eligibility
18 Years to 69 Years · Male only
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 25, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

An Exploratory Investigation to Identify if Dame Product's "DLM" Works to Improve Sexual Desire and Mood in Females

NCT05130411
View directory record Official record
Conditions
Sexual Desire Disorder
Interventions
DLM - Test product
Dietary Supplement
Lead sponsor
Dame Products, Inc.
Industry
Eligibility
24 Years to 65 Years · Female only
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Jan 9, 2022 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Bupropion Hydrochloride in Improving Sexual Desire in Women With Breast or Gynecologic Cancer

NCT03180294
View directory record Official record
Conditions
Breast Carcinoma, Cervical Carcinoma, Ovarian Carcinoma, Postmenopausal, Uterine Corpus Cancer, Vaginal Carcinoma, Vulvar Carcinoma
Interventions
Bupropion 150 mg XL, Placebo
Drug
Lead sponsor
NRG Oncology
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
362
States / cities
Anaheim, California • Antioch, California • Baldwin Park, California + 262 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Phase 3 Interventional Results available

Flibanserin for the Treatment of Hypoactive Sexual Desire Disorder in Postmenopausal Women in North America

NCT01057901
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
Flibanserin, Placebo
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
35 Years and older · Female only
Enrollment
748 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
84
States / cities
Birmingham, Alabama • Tucson, Arizona • Tuscon, Arizona + 73 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2014 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 1Phase 2 Interventional

Phase 1b/2a Unblinded Study of Responses in Premenopausal Women With HSDD to Lorexys Evaluating Efficacy and Safety

NCT01857596
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder (DSM-IV-TR Defined), Sexual Interest/Arousal Disorder (DSM-5 Defined)
Interventions
bupropion, Lorexys low-dose, Lorexys moderate-dose
Drug
Lead sponsor
S1 Biopharma, Inc.
Industry
Eligibility
25 Years to 50 Years · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
2
States / cities
Beachwood, Ohio • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 27, 2014 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional Results available

A Mindfulness-based Intervention for Older Women With Low Sexual Desire

NCT03232801
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder, Sexual Dysfunction, Female Sexual Dysfunction
Interventions
mindfulness-based multicomponent intervention, general health education group
Behavioral
Lead sponsor
University of Pittsburgh
Other
Eligibility
50 Years and older · Female only
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Results available

Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients

NCT00698035
View directory record Official record
Conditions
Sexual Dysfunction, Physiological
Interventions
Testosterone Cream, Estring
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Phase 3 Interventional Results available

A One-year Safety Study of Flibanserin to Treat Pre-Menopausal Women With Hypoactive Sexual Desire Disorder (HSDD).

NCT00441558
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
Flibanserin
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
1,723 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
173
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 130 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2014 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 3 Interventional

Extension Study to Assess Persistence of Benefit of LibiGel for the Treatment of Hypoactive Sexual Desire Disorder (HSDD)

NCT01235754
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
transdermal testosterone gel 1%, placebo gel
Drug
Lead sponsor
BioSante Pharmaceuticals
Industry
Eligibility
30 Years to 66 Years · Female only
Enrollment
626 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
98
States / cities
Hoover, Alabama • Huntsville, Alabama • Mobile, Alabama + 91 more
Source: ClinicalTrials.gov public record
Updated Jan 9, 2013 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Lybrido for Female Sexual Dysfunction

NCT01432665
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo, Sildenafil, Testosterone
Drug
Lead sponsor
Emotional Brain NY Inc.
Industry
Eligibility
21 Years to 70 Years · Female only
Enrollment
196 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2011
U.S. locations
14
States / cities
San Diego, California • Washington D.C., District of Columbia • Brooksville, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2013 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Not applicable Interventional

A Study Evaluating the Effects of Topical Clitoral Estradiol Cream in Post Menopausal Women

NCT02859285
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Placebo vulvar cream, Estradiol vulvar cream
Other
Lead sponsor
ProHealth Care, Inc
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Waukesha, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 12, 2020 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 2 Interventional

Study of DHT-Gel to Treat the Symptoms of Low Testosterone in Men 55-80

NCT00163566
View directory record Official record
Conditions
Hypogonadism, Late Onset Hypogonadism, Low Testosterone
Interventions
Dihydrotestosterone (0.7%) in hydroalcoholic gel
Drug
Lead sponsor
ASCEND Therapeutics
Industry
Eligibility
55 Years to 80 Years · Male only
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
16
States / cities
Phoenix, Arizona • Torrance, California • Gainesville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2022 · Synced Jul 20, 2026, 6:40 PM EDT
Terminated Phase 3 Interventional Results available

12 Week Safety Trial of Flibanserin in Depressed Women Taking an SSRI or SNRI With Decreased Sexual Desire and Distress

NCT01040208
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological, Depression
Interventions
flibanserin 50 mg to 100 mg qhs, flibanserin 100 mg qhs, placebo 2 tablets qhs
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 50 Years · Female only
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
42
States / cities
Costa Mesa, California • Fresno, California • National City, California + 36 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2016 · Synced Jul 20, 2026, 6:40 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

An Open Label Study to Assess the Effect of Euryco-10® Oral Dietary Supplement in Senior Men

NCT04584918
View directory record Official record
Conditions
Healthy Aging
Interventions
Not listed
Lead sponsor
Innovus Pharmaceuticals, Inc.
Industry
Eligibility
55 Years and older · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Testosterone Trials in Older Men

NCT00799617
View directory record Official record
Conditions
Andropause
Interventions
AndroGel® (testosterone gel), Placebo
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
65 Years and older · Male only
Enrollment
790 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2018
U.S. locations
12
States / cities
Birmingham, Alabama • La Jolla, California • Torrance, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2019 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Results available

A Study in Men With Low Testosterone to Measure the Effects of Testosterone Solution on Testosterone Levels, Sex Drive and Energy

NCT01816295
View directory record Official record
Conditions
Hypogonadism
Interventions
Testosterone Solution, Placebo Solution
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Male only
Enrollment
715 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
45
States / cities
Homewood, Alabama • Chandler, Arizona • Glendale, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2015 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Results available

24-week Placebo-controlled Trial of Flibanserin Once Daily in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00360529
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
flibanserin
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
880 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
40
States / cities
Mobile, Alabama • South Birmingham, Alabama • Phoenix, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2016 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 3 Interventional

Study of Transdermal Testosterone Patches in Surgically Menopausal Women With Low Libido

NCT00331214
View directory record Official record
Conditions
Hypoactive Sexual Desire Disorder
Interventions
Testosterone Transdermal System, placebo patch
Drug
Lead sponsor
Warner Chilcott
Industry
Eligibility
20 Years to 70 Years · Female only
Enrollment
533 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Jul 20, 2026, 6:40 PM EDT
Completed Phase 3 Interventional Results available

Fixed 100 mg Every Evening of Flibanserin vs Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder

NCT00996164
View directory record Official record
Conditions
Sexual Dysfunctions, Psychological
Interventions
Flibanserin, Placebo
Drug
Lead sponsor
Sprout Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Female only
Enrollment
1,090 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
75
States / cities
Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 61 more
Source: ClinicalTrials.gov public record
Updated May 18, 2014 · Synced Jul 20, 2026, 6:40 PM EDT